Ribavirin for Hemorrhagic Fever With Renal Syndrome
Status:
Enrolling by invitation
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Hemorrhagic Fever with Renal Syndrome (HFRS) is caused by a virus acquired by contact with
chronically infected rodent hosts. HFRS is present throughout Korea. Treatment consists
mainly of supportive care with careful attention to control of blood pressure and fluid
balance and/or dialysis. Early initiation of IND Intravenous Ribavirin has been shown to be
an effective treatment for HFRS and may prevent the need for dialysis. It is important to
initiate therapy based on a diagnosis consistent with HFRS and a history that makes exposure
likely. This study will monitor the clinical events that occur with HFRS as well as the
safety and efficacy of Ribavirin.
Phase:
Phase 2
Details
Lead Sponsor:
U.S. Army Medical Research and Development Command U.S. Army Medical Research and Materiel Command